23269-70-7

Basic information

• Product Name: N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)acetamide
• Synonyms: N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)acetamide
• CAS NO: 23269-70-7
• Molecular Weight: 235.266
• Mol File: 23269-70-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)acetamide(23269-70-7)
• EPA Substance Registry System: N-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)acetamide(23269-70-7)

Safety Data

• Hazardous Substances Data: 23269-70-7(Hazardous Substances Data)

Upstream product

• 17012-22-5 methyl 4-acetamidobenzoate 
• 619-45-4 4-methoxycarbonyl aniline 
• 150-13-0 4-amino-benzoic acid 
• 94-09-7 p-aminoethylbenzoate 
• 5338-44-3 ethyl p-acetamidobenzoate 
• 75-15-0 carbon disulfide 
• 41764-73-2 N-[4-(hydrazinecarbonyl)phenyl]acetamide 

Downstream Products

• 203268-83-1 5-(4-aminophenyl)-1,3,4-oxadiazole-2-thiol 

Relevant articles and documents

1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities

1,2,4-Triazole and 1,3,4-oxadiazole analogues are of interest due to their potential activity against microbial and malarial infections. In search of suitable antimicrobial and antimalarial compounds, we report here the synthesis, characterization and biological activities of 1,2,4-triazole and 1,3,4-oxadiazole analogues (SS 1-SS 10). The molecules were characterized by IR, mass, 1H NMR, 13C NMR and elemental analysis. The in vitro antimicrobial activity was investigated against pathogenic strains, the results were explained with the help of DFT and PM6 molecular orbital calculations. In vitro cytotoxicity and genotoxicity of the molecules were studied against S. pombe cells. In vitro antimalarial activity was studied. The active compounds were further evaluated for enzyme inhibition efficacy against the receptor Pf-DHFR computationally as well as in vitro to prove their candidature as lead dihydrofolate reductase inhibitors.